AA
NVAX icon

ALPS Advisors’s Novavax NVAX Stock Holding History

ALPS Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.47M Buy
181,025
+47,593
+36% +$431K 0.01% 465
2025
Q4 		$897K Buy
133,432
+57,675
+76% +$435K 0.01% 584
2025
Q3 		$657K Sell
75,757
-11,576
-13% -$90.1K ﹤0.01% 626
2025
Q2 		$550K Sell
87,333
-26,898
-24% -$178K ﹤0.01% 613
2025
Q1 		$732K Sell
114,231
-15,299
-12% -$126K ﹤0.01% 544
2024
Q4 		$1.04M Buy
+129,530
New +$1.25M 0.01% 470
2023
Q2 		– Sell
-56,775
Closed -$393K – 1021
2023
Q1 		$393K Buy
56,775
+3,560
+7% +$32.8K ﹤0.01% 626
2022
Q4 		$547K Buy
53,215
+10,502
+25% +$185K ﹤0.01% 575
2022
Q3 		$777K Sell
42,713
-3,642
-8% -$158K 0.01% 517
2022
Q2 		$2.38M Buy
+46,355
New +$2.4M 0.02% 283

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ALPS Advisors's NVAX Position: Q1 2026 in Review

ALPS Advisors increased its Novavax (NVAX) stake by 36% in Q1 2026, buying an estimated $431K and bringing the position to 181,025 shares worth $1.47M. The position accounts for 0.01% of the portfolio, ranked #465.

ALPS Advisors first reported a position in NVAX in Q2 2022 and has held it in 10 quarters since. The position peaked at $2.38M in Q2 2022. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • ALPS Advisors held 181,025 shares of Novavax worth $1.47M as of Q1 2026.
  • ALPS Advisors bought 47,593 Novavax shares in Q1 2026, an estimated $431K.
  • Novavax made up 0.01% of ALPS Advisors's portfolio in Q1 2026, its #465 holding.
  • ALPS Advisors first reported a position in Novavax in Q2 2022 and has held it in 10 quarters since.
  • ALPS Advisors's Novavax position peaked at $2.38M in Q2 2022.
  • 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.